• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in lipidology >Lipid metabolism
【24h】

Lipid metabolism

机译：脂质代谢

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interest in lipid changes mediated by several classes of anti-inflammatory drugs, used to treat Rheumatoid arthritis (RA), has been increasing in recent years. Most recently, Tofacitinib, a novel oral Janus kinase inhibitor, shown recently to be broadly similar to tumour necrosis factor (TNF) blockade in its clinical efficacy, was also reported to raise both LDL and HDL-cholesterol levels. This finding follows prior evidence of a rise in cholesterol and HDL-cholesterol with the interleukin-6 receptor blocker, Tocilizumab, as reviewed, and two recent systematic reviews/meta-analyses confirming TNF blocking therapy also elevates both total and HDL-cholesterol levels .
机译：近年来，对用于治疗类风湿性关节炎（RA）的几种抗炎药介导的脂质变化的兴趣不断增长。最近，据报道新的口服Janus激酶抑制剂Tofacitinib在临床疗效上与肿瘤坏死因子（TNF）阻断作用大体相似，据报道它同时提高LDL和HDL-胆固醇水平。该发现是在先前证据表明白介素6受体阻滞剂Tocilizumab导致胆固醇和HDL胆固醇升高的基础上进行的，最近的两项系统综述/元分析证实TNF阻断疗法也同时升高了总胆固醇和HDL胆固醇水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号